Hagedorn Research Institute

Department of Stem Cell Biology

Niels Steensens vej 6

DK-2820 Gentofte

 

novonordisk.com

 

Project leader

 
Dr. Mattias Hansson
 
Phone +45 4442 9137
Fax +45 4443 8000
E-Mail  

Project staff

 
Dr. Christian le Fèvre Honoré
 
Fax +45 4443 8000
E-Mail  

 

 
Dr. Nicolaj  Strøyer Christophersen   
 
Phone +45 4442 4047
Fax +45 4443 8000
E-Mail  

Institute presentation

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.

Hagedorn Research Institute (HRI) in Gentofte, Denmark is a fully integrated part of Novo Nordisk. Our vision is to find a cure for diabetes and its complications and to identify new opportunities for treating diabetes. Our core focus is the effort to identify new biology-based targets for potential drugs to feed Novo Nordisk’s pipeline within the key areas of diabetes pathogenesis, treatment and cure. The aim of the Stem Cell Biology department is to develop cell replacement therapy into a viable option for treating Diabetes Mellitus. The reconstitution of a functional beta cell mass can restore blood glucose homeostasis in diabetic patients and eliminates the need for insulin injections. Our main objective is to generate clinical-grade pancreatic beta cells from pluripotent stem cells by harnessing their differentiation potential and to recapitulate the complex process of beta cell formation in vitro.